reason report
bottom line reiter op modestli increas
estim follow anoth sales/ep beat
includ impress procedur growth perform
handili beat consensu even top
believ elev buysid expect light
ytd out-performance management bump procedur outlook
vs prior think still set upsid
vs consensu magnitud system revenue upsid
bit less pronounc vs prior qtr explain
reason increas placement op leases/usage-bas capit
agreement us use balanc sheet acceler unit placement
right strategi especi given higher system util
engend futur revenue stream eventu materi
management estim npv futur revenue continu
see multipl avenu estim upsid -- -even higher
forecast -- -a new product cycl across system sp ion
instrument stapler new vessel sealer begin unfold
compani drive increas penetration/ accept grow set
intern market new us gen surgeri procedur area
dcf-base pt goe vs higher estim
solid qtr mark procedur system placement upsid
margin out-performance report revenue vs
consensu driven mostli instrument accessori revenue
upsid vs consensu procedur upsid
off-set slightli expect system revenue vs
consensu despit better-than-expect system placement
ww vs consensu includ higher-than-project
placement oper leas less in-qtr revenue vs street model
 gm beat us/consensu
adj ebita mgn vs consensu lpe
opex came lower expect lower tax rate vs think also
help ep ultim beat our/street
compani inform leerink partner llc research
revenu mm ep ex item stock expens defer revenu amort
medic suppli devic
dcf wgtd average cost
net debt total capit
price-to-earnings lt ep growth
pleas refer page import disclosur price chart analyst certif
y/i procedur growth beat lead
outlook increas log ww procedur growth
consensu repres y/i growth acceler
highest growth sinc us grew y/i vs
fuel continu momentum us surgeri led hernia
colorect well anoth qtr better-than-expect urolog
gyn trend ou y/i growth vs ahead
estimate driven strength uk japan procedur growth
track follow new approv april driver
off-set moder china growth expect capac expans
region depend govern quota add new system
guidanc increas vs think rang
still leav room upsid new procedur
high end guidanc
ww placement solidli albeit higher op
leas limit in-qtr upsid high level problem
view us system drove upsid place compar
our/consensu estimate meaning out-performance come
 xi estimate sp unit place vs
estimate intern placement came
think unit lower cost robot think xi
unit consist find on-going
check link aggress place system
financ altern oper leas well usage-bas
arrang high volum account book
op leas ww placement
management expect continu increas think type
placement benefici move physician across
hospit definit da vinci camp ahead new
entrant look enter robot marketplac sever year
 multipl new platform come
applic submit ship sp unit
urolog repres initi indic sp approv
management plan use first access site data gener
custom feedback stress multi-year pathway
compani pursu follow-on indic sp transan
extraperiton colorect transor pend fda approv
submit model system placement us
total system placement assum asp
translat revenu
model us system respect
assum asp
pipelin initi also track vessel sealer
extend second qtr us launch sureform stapler
approv launch full scale launch
help drive increas penetr thorac bariatr categori
ion platform flexibl cathet robot lung biopsi management
submit first indic anticip
approv like model platform
revenu revenue respect
revenue forecast increas respect
reflect aggress procedur forecast instrument
 accessori revenue offset lower system revenue
lower despit higher system placement assumpt model
contempl higher placement come oper leas
futur project procedur growth model
ww system placement model op-ex growth
increas modestli sit y/i
rate share outperform ultim believ key valu driver
place stock work intermediate-to-longer-term acceler
procedur growth new product cycl momentum continu uniqu robot
colorect bariatr thorac head neck other acceler growth procedur
adopt intern dvp da vinci prostatectomi europ japan new product cycl
 xi sp flexibl cathet robot help sustain above-averag top- bottom-lin
double-digit growth system advanc continu open increment surgery/revenu
sourc time near-to-intermedi term continu see multipl avenu
drive estim upsid new product cycl gradual unfold sp lung biopsi
compani drive increas penetration/accept grow set intern market
valuat base dcf analysi yield pt discount rate
calcul use capm model price-to-earnings basi pt translat
cash ep respect current trade ex-cash
basi incl cash ex-cash incl cash vs broader market cap
med-tech average pt impli appli
adj ep less int incom cash believ isrg premium group
product cycl help drive increas penetr still-larg under-penetrated
risk valuat includ high volatil wide-trad rang stock
compani relianc singl product robot potenti chang wors hospit
capit spend environ continu debat around cost/benefit come
adopt robot procedur current project valuat could risk
gyn/uro trend slow greater degre model newer gener surgeri robot
procedur slower expect adopt forecast anticipated-to-launch
nexgen sp platform delay fail gain traction launch compani cant
achiev revenu contribut model flexibl cathet robot program
key risk includ ou growth slower anticip -- -either due delay
develop new japan procedur opportun and/or new china system tender/quota
newer robot entrant mdt/jnj beyond come onto scene
result competit trial potenti caus hospit purchas cycl elong given
robot solut evalu sg invest combat competit
develop new market lead greater opex spend -- -potenti limit near-term earn
power -- -v weve model
dollar million except ep
compani report streetaccount leerink partner llc estim
segment result ex total revenu first order analyt consensu
dollar million except ep
compani report leerink partner llc estim
compani report leerink partner llc estim
dollar million except per share data
good sold ex-amort/sbc/def cog
disc op debt ext /recap net tax
pre-split dilut averag share million
post-split dilut averag share million
compani report leerink partner llc estim
note adopt revenu contract custom effect januari use full retrospect method prior period tabl present financi result restat reflect effect adopt
dollar million except per share data
total
compani report leerink partner llc estim
note adopt revenu contract custom effect januari use full retrospect method prior period tabl present financi result restat reflect effect
